Certified by Founder
Lodge
Bryleos
start up
United States
- Johnson City, Tennessee
- 14/06/2023
- Seed
- $5,000,000
Early clinical stage therapeutics company developing BNAD101, a patent-pending oral composition of NAD+ clinically proven to increase intracellular NAD+. BNAD101 is a potential high-value medicine to treat challenging and costly neurological disorders.
In 2022, the Company completed its double-blind, placebo-controlled proof of concept study at the Institute of Systems Biology. The study of 60 healthy adults demonstrated BNAD101 had a 52% increase in intracellular NAD levels against placebo within just 5 days, effectively validating the potential of BNAD101 in treating not only chronic neurological conditions but conditions were swift response is critical.
Bryleos: More Life While Living
- Industry Biotechnology Research
- Website https://bryleos.com/
- LinkedIn https://www.linkedin.com/company/bryleos/
Vector 👻 | $10,000,000 | (May 14, 2026)
Avant Genomics | $3,000,000 | (May 14, 2026)
Data Mission | $1,000,000 | (May 14, 2026)
Origin Lab | $8,000,000 | (May 14, 2026)
CREATE Medicines | $122,000,000 | (May 14, 2026)
Synthetic | $10,000,000 | (May 14, 2026)
SwishX | $2,200,000 | (May 14, 2026)
Dolfin | $2,460,580 | (May 14, 2026)
Urologic Health | $11,000,000 | (May 14, 2026)
4AM | $4,000,000 | (May 13, 2026)
Adfin | $18,000,000 | (May 13, 2026)